Neonatal abstinence syndrome (NAS) is a result of the sudden discontinuation of fetal
exposure to substances that were used or abused by the mother during pregnancy …

Neonatal Abstinence Syndrome | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Objectives: The prevalence of opioid use disorder (OUD) during pregnancy is increasing.
Practical recommendations will help providers treat pregnant women with OUD and reduce …

Neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure is an
increasing problem. Variability in assessment and treatment of NAS has been attributed to …

Background Current pharmacologic treatment of the neonatal abstinence syndrome with
morphine is associated with a lengthy duration of therapy and hospitalization …

Opiate use in pregnancy has increased dramatically over the past decade and now
represents a major public health problem. More women are using prescription opioids …

Physicians should be aware of the complexity of the maternal, fetal, and infant factors that
combine to create the infant's display of NAS, and incorporate these aspects into …

Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants
develop after intrauterine maternal drug exposure. All infants with documented in utero …

Objective: Neonatal abstinence syndrome (NAS) is a drug withdrawal syndrome
experienced by opioid-exposed infants. There is no standard treatment for NAS and surveys …

Safety of maternal drug therapy during breastfeeding may be assessed from estimated
levels of drug exposure of the infant through milk. Pharmacokinetic (PK) principles predict …